Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.5098
+0.00981.96%
Post-market: 0.51000.0002+0.04%19:59 EDT
Volume:2.67M
Turnover:1.36M
Market Cap:184.29M
PE:-0.81
High:0.5262
Open:0.5001
Low:0.4980
Close:0.5000
Loading ...

Lexicon price target lowered to $4 from $6 at H.C. Wainwright

TIPRANKS
·
23 Nov 2024

Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $4 From $6

THOMSON REUTERS
·
23 Nov 2024

Lexicon Pharmaceuticals to Cut 60% of Workforce

MT Newswires Live
·
22 Nov 2024

UPDATE 1-Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback

Reuters
·
22 Nov 2024

Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization

Dow Jones
·
22 Nov 2024

Lexicon falls on restructuring program

seekingalpha
·
22 Nov 2024

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Reuters
·
22 Nov 2024

Lexicon to eliminate commercial organization, focus on clinical development

TIPRANKS
·
22 Nov 2024

BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Reuters
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Prioritizing Strong R&D Pipeline Including Ongoing Studies in Dpnp, HCM and Obesity

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Total Reduction of Approximately 60 Percent of Employees, Effective for Most Affected Employees by December 31

THOMSON REUTERS
·
22 Nov 2024

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Elimination of Promotional Efforts for Inpefa, Planned Commercial Activities for Zynquista

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Efforts Expected to Reduce 2025 Operating Costs by $100 Mln

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Inc: Receipt of a "Deficiencies Preclude Discussion" Letter From FDA Regarding Nda for Zynquista

THOMSON REUTERS
·
22 Nov 2024

Lexicon Pharmaceuticals Appoints Ivan Cheung to Board

TIPRANKS
·
21 Nov 2024

Lexicon Appoints Ivan H. Cheung to Board of Directors

THOMSON REUTERS
·
21 Nov 2024

Press Release: Lexicon Appoints Ivan H. Cheung to Board of Directors

Dow Jones
·
21 Nov 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week

Simply Wall St.
·
18 Nov 2024